Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|June 11, 2025
Association between ABO blood groups and pancreatic cancer outcomes: A systematic review and meta-analysisTulio L Correa, Mario Keko, Pedro Danielian, et al.
Investigational New Drugs|March 5, 2024
A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancerAndrew H Ko, Andrew L Coveler, Benjamin L Schlechter, et al.
Investigational New Drugs|September 17, 2025
Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumorsAlejandro Falcón, Santiago Ponce, Gregory M Cote, et al.
Cancer Research Communications|May 12, 2026
A Multi-center Retrospective Outcomes Analysis of Patients with Localized Synovial SarcomaStefano Testa, Maggie Yuxi Zhou, Brian C Schulte, et al.
Molecular Cancer Therapeutics|June 6, 2020
Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor CellsSpas Dimitrov-Markov, Javier Perales-Patón, Bruno Bockorny, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2020
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor ModelsMyriam Fabre, Cristina Ferrer, Saioa Domínguez-Hormaetxe, et al.
Liver Cancer|May 14, 2026
A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular CarcinomaAnthony B El-Khoueiry, Christopher H Lieu, Ghassan K Abou-Alfa, et al.
Molecular Cancer Therapeutics|April 15, 2018
RAS-MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i>-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK BlockadeBruno Bockorny, Maria Rusan, Wankun Chen, et al.
Nature Medicine|January 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A Yap, Randy F Sweis, Ulka Vaishampayan, et al.
Investigational New Drugs|May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumorsAlejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Pageof 5